[Remote] Director, Regional Accounts Market Access - West at Axsome Therapeutics Inc

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Bachelor’s degree required; MBA preferred
Over a decade of experience in biotechnology and/or pharmaceuticals
10+ years of experience in regional accounts market access, preferably in the pharmaceutical industry

Responsibilities

Strategic Market Leadership
Develop, refine, and execute regional market access strategies
Anticipate trends, identify emerging threats, and unlock new opportunities
Align tactical account plans with company objectives, financial targets, and market dynamics
Payer & Stakeholder Influence
Forge deep, trust-based relationships with executive-level decision-makers
Partner with trade relations, medical directors, and clinical leaders
Collaborate with HOL and Medical Affairs
Advise marketing teams on customer-specific messaging
Support field sales and regional field managers
Lead Vera’s presence at industry meetings and customer summits
Oversee performance management, compliance, and utilization audits

Skills

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free